Exact Sciences Bundle
Who really controls Exact Sciences?
Exact Sciences, founded in 1995 in Madison, Wisconsin, scaled into a global cancer-diagnostics leader after acquiring Genomic Health for about $2.8 billion in 2019; it reported over $2.6 billion revenue in 2024 and trades as EXAS on Nasdaq.
Major ownership is institutional, with mutual funds and ETFs holding the largest stakes, while founders and insiders retain smaller, influential positions; see governance and ownership shifts driven by M&A and capital raises. Exact Sciences Porter's Five Forces Analysis
Who Founded Exact Sciences?
Founders and early ownership at Exact Sciences trace to 1995, when Stanley J. Lapidus, Anthony N. Shuber and scientific collaborators including Dr. Lawrence R. Ladd and Dr. John W. Laird established the company to detect cancer via stool- and blood-based DNA markers; Lapidus served as founding CEO and held the leading founder stake pre-IPO.
Founding team
Co-founders: Stanley J. Lapidus, Anthony N. Shuber, Dr. Lawrence R. Ladd, Dr. John W. Laird; scientific focus on DNA-based cancer detection.
Early equity
Initial equity splits were not publicly detailed; Lapidus held a leading founder stake that experienced typical venture dilution before the 2001 IPO.
Early investors
Backers included venture investors and strategic angels common to diagnostics startups of the 1990s and 2000s; insiders and early VCs owned minority shares by the 2001 offering.
Governance & vesting
Founders and early employees typically faced four-year vesting with one-year cliffs and standard protective provisions: ROFR, co-sale and buy-sell restrictions.
Leadership transition
Founder influence declined as Lapidus left executive roles in the mid-2000s and later capital raises and strategic pivots shifted control to institutional holders.
Legal and control
No widely reported founder legal disputes altered control; ownership migrated progressively to institutions through recapitalizations as the firm refocused on colorectal screening.
Early ownership dynamics set the stage for later institutional concentration; for details on company revenue and strategy see Revenue Streams & Business Model of Exact Sciences.
Key facts and data
Founders, vesting, dilution and ownership transition summarized with earliest public filings and governance norms.
- Company founded in 1995 by Lapidus, Shuber, Ladd and Laird.
- Lapidus served as founding CEO and held leading founder stake pre-IPO.
- 2001 IPO diluted insiders and early VCs to a minority position relative to public float.
- By mid-2000s, institutional investors became primary stakeholders as founders' stakes were diluted through financings and strategic pivots.
Exact Sciences SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Exact Sciences’s Ownership Changed Over Time?
Key events that reshaped Exact Sciences ownership include the 2001 Nasdaq IPO, the 2009–2014 refocus on stool‑DNA leading to Cologuard FDA approval, the 2019 $2.8B Genomic Health acquisition paid in cash and EXAS stock, and multiple convert and at‑the‑market financings in 2020–2023 that increased institutional float and diluted early insiders.
| Period | Ownership Shift | Impact |
|---|---|---|
| 2001 IPO | Public listing on Nasdaq (EXAS); institutional and retail float growth | Initial market cap in the hundreds of millions; early insiders diluted by secondary offerings |
| 2009–2014 | Strategic refocus to stool‑DNA; Cologuard FDA approval in 2014 | Attracted growth healthcare funds; rising institutional ownership and index eligibility |
| 2014–2019 | Commercial scale‑up via multiple secondaries | Ownership concentrated among mutual funds and ETFs |
| 2019 | Acquisition of Genomic Health for $2.8B (cash + EXAS stock) | EXAS shares issued to Genomic Health holders (notably Vanguard, BlackRock), reshaping cap table |
| 2020–2023 | Convertible notes and ATM equity raises | Modest share count increase; institutional float expanded to support R&D and M&A |
| 2024–2025 | Dominance of index and active institutional holders | EXAS market cap roughly $10–15B; top holders: Vanguard ~10–12%, BlackRock ~8–10%; insiders low single digits |
Ownership evolution moved control from founders and early insiders to a dispersed, institution‑led register; proxy advisors and passive ETF voting power now exert significant governance influence across strategy, R&D pacing, and M&A discipline.
Major shareholders and structural drivers
By late 2024/early 2025 institutional investors—especially index and large active managers—dominated Exact Sciences shareholders, while insider ownership remained in the low single digits.
- The Vanguard Group commonly reported around 10–12% of EXAS in 13F/FactSet tallies
- BlackRock frequently held about 8–10%; State Street, T. Rowe Price, Wellington, and Fidelity also appeared among top holders
- Post‑2019 Genomic Health share issuance amplified passive and fundamental institutional stakes, further diluting legacy insiders
- Convertible financings and ATM programs from 2020–2023 modestly increased float to fund growth and inorganic deals
For ownership details, 13F filings, Form 4 insider reports, and the company proxy provide authoritative snapshots; see this industry analysis for context Competitors Landscape of Exact Sciences
Exact Sciences PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Exact Sciences’s Board?
The Exact Sciences board in 2024–2025 reflects a mix of executives and independent directors with diagnostics, payer, and commercialization experience; governance follows a one-share-one-vote model so control tracks economic ownership and no dual-class or golden shares are reported.
| Director | Role | Notable background |
|---|---|---|
| Kevin T. Conroy | Chairman and CEO | Insider executive; significant but not controlling ownership |
| Katherine S. Zanotti | Independent Director | Commercialization and diagnostics experience |
| Michael S. Wyzga | Independent Director | Payer and reimbursement expertise |
| M. Kathleen Behrens | Independent Director | Healthcare leadership and governance |
| Scott Coward | Independent Director | Commercial operations and strategy |
| Sandra E. Peterson | Independent Director | Corporate governance and public company oversight |
Institutional investors such as Vanguard, BlackRock, and State Street rank among the largest shareholders by reported holdings in 2024–2025 but hold no designated board seats; voting outcomes are driven by institutional stewardship, proxy advisors, and dispersed retail holders.
Board and Voting Dynamics
Exact Sciences uses a one-share-one-vote structure; board composition and institutional voting shape governance rather than special share classes.
- Board includes independent directors with diagnostics, payer, and commercialization expertise
- CEO Kevin T. Conroy is a significant insider holder but not a controlling owner
- Top institutional holders (Vanguard, BlackRock, State Street) influence outcomes via proxy voting
- Proxy advisors ISS and Glass Lewis and stewardship teams materially affect voting on pay and governance
For additional context on corporate purpose and leadership statements see Mission, Vision & Core Values of Exact Sciences.
Exact Sciences Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Exact Sciences’s Ownership Landscape?
Recent ownership trends at Exact Sciences show greater institutional concentration, with passive managers growing larger stakes and insider ownership remaining in the low single digits through mid-2025; capital activity from 2022–2024 funded integration and R&D while prioritizing growth over buybacks.
| Topic | Key Data (2022–mid‑2025) | Implication |
|---|---|---|
| Capital & M&A | Integration of Genomic Health; R&D expansion in precision oncology and multi‑cancer early detection; funded by improved operating cash flow and prior convertible financings | Focus on growth investment; no large buybacks reported for 2024–2025 |
| Institutional Ownership | Vanguard and BlackRock frequently top holders; combined passive ownership often > 20% in many 13F snapshots | Greater index-driven flows; concentration with large asset managers |
| Insider Ownership | Low single digits (reflecting dilution from financing and stock-based M&A) | Limited founder/insider control; governance shaped by large institutions |
| Share Count & Liquidity | Secondary and ATM issuances increased float; 2024–2025 trading volumes remained robust | Inclusion in healthcare/biotech indices; supports passive inflows |
| Leadership | Kevin Conroy serves as CEO and Chairman through 2024–2025 | Continuity attractive to long‑term institutional holders |
| Activism & Governance | Sector‑level activist activity rose; Exact Sciences reported no major activist confrontations as of mid‑2025 | Emphasis on clinical evidence, reimbursement durability, and stewardship engagement |
| Outlook | Management signals continued independence and selective M&A; no moves toward privatization or dual‑class structure | Ownership shifts likely driven by index weight, potential follow‑ons, and fund rotations |
Institutional concentration and index inclusion shape Exact Sciences ownership dynamics, while management emphasizes pipeline funding and selective acquisitions over buybacks; see analysis in Growth Strategy of Exact Sciences for related strategic context.
Capital posture 2022–2024
Integration of Genomic Health and expanded R&D were financed largely through operating cash flow improvements and earlier convertible financings, supporting growth allocation over repurchases.
Institutional investor mix
Top shareholders typically include large index managers; combined passive ownership often exceeds 20%, increasing index‑driven inflows and trading liquidity.
Insider ownership
Insider stakes remain in the low single digits due to dilution from financings and stock‑based M&A, limiting founder control and elevating institutional governance influence.
Governance and activism
Rising passive ownership and stewardship engagement shift focus to governance, clinical evidence, and reimbursement durability; no major activist confrontations disclosed as of mid‑2025.
Exact Sciences Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Exact Sciences Company?
- What is Competitive Landscape of Exact Sciences Company?
- What is Growth Strategy and Future Prospects of Exact Sciences Company?
- How Does Exact Sciences Company Work?
- What is Sales and Marketing Strategy of Exact Sciences Company?
- What are Mission Vision & Core Values of Exact Sciences Company?
- What is Customer Demographics and Target Market of Exact Sciences Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.